Arms Pharmaceutical touts oral spray for upper respiratory tract infections

Arms Pharmaceutical touted data from a proof-of-concept clinical trial evaluating its oral spray formulation, Arms-I, for upper respiratory tract infections.

The placebo-controlled trial demonstrated that the oral spray formulation is safe, well-tolerated and reduced influenza symptoms, according to the Cleveland-based pharmaceutical company.

Get the full story at our sister site, Drug Delivery Business News.

The post Arms Pharmaceutical touts oral spray for upper respiratory tract infections appeared first on MassDevice.

from MassDevice http://ift.tt/2k4jAhF